Dermatological
Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.
Argenx has discontinued Vyvgart for the rare skin disease as other potential candidates linger in the very early stages of development.
Having built its portfolio from university collaborations and targeted in-licensing, the UK firm now hopes to validate its business model with Phase II readouts in 2025.
With Jakafi slated to lose US patent protection in 2028, Incyte is looking to GVHD launch product Niktimvo and label expansions for Opzelura, Monjuvi and Zynyz to drive late-decade growth.
Scrip surveys some of the more interesting Phase III clinical trial readouts expected this year.
The US biotech is paying $250m upfront to the Danish group in what is the second STAT6 deal secured in the past three weeks.
The head of Chugai's new $200m venture capital fund talks to Scrip about its investment priorities.
The company reported positive Phase II data from the BEACON trial testing the c-Kit inhibitor in chronic spontaneous urticaria and said it is planning a Phase IIb/III program.
Japanese major highlights at R&D Day key late-stage pipeline assets set to be filed for approval over the next few years, which it says have a combined peak sales potential of $10-20bn, and which could help it weather the expiry of current blockbuster Entyvio.
Nemluvio is the first IL-31 inhibitor approved by the US FDA for atopic dermatitis and will compete with Sanofi/Regeneron’s Dupixent and other, newer IL-13 inhibitors.
Topical, oral and biologic drugs have made a difference for patients with atopic dermatitis, but full control remains elusive for many, with the heterogeneous condition, leaving open a door for new medications.
CEO Christophe Bourdon talked to Scrip about the company’s revitalization as revenue grew 10% in the third quarter.
The US healthcare giant says that icotrokinra could provide an “industry-leading combination of significant skin clearance with demonstrated tolerability in a once-daily pill" after succeeding in late-stage trials.
Incyte is looking to expand in dermatology, but two products at the center of its Escient buyout earlier this year have run into some trouble.
The Spanish company's Lilly-partnered atopic dermatitis drug is enjoying a decent launch in Germany and in other European countries, "we are getting the price that we wanted," claims CEO Carlos Gallardo.
Rocatinlimab met its Phase III endpoints with results that appear uncompetitive with AD market leader Dupixent, while Uplizna may offer a compelling twice-yearly gMG treatment option.
An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.
Organon will pay $175m up front for Roivant subsidiary Dermavant and its topical therapy for psoriasis Vtama. The acquirer is betting on growth from adding atopic dermatitis to Vtama’s label.
New pivotal data on Regeneron and Sanofi’s antibody in chronic urticaria are underwhelming, though probably sufficient for approval. A green light may beckon in bullous pemphigoid, too.
The Danish firm’s dermatology products have made significant strides in the past six months, leading to an upwards revision of its sales forecast for full-year 2024.